文献速递胸部肿瘤放疗放疗物理与技术

电磁导航支气管镜中新型基准标记放置引导系统改善呼吸运动追踪

Improved respiratory motion tracking through a novel fiducial marker placement guidance system during electromagnetic navigational bronchoscopy (ENB).
PubMed 文献 · Radiat Oncol · 2019-07-11

本研究回顾性分析了2015年5月至2017年1月接受机器人立体定向消融放疗(SABR)的128例患者共147个肺部病灶,比较使用与未使用基准标记放置引导系统(FPGS)时被追踪基准标记数量的差异;结果显示使用FPGS的病灶每分次被追踪标记数中位数显著提高(p<0.001),并发症率低且两组无统计学差异(p=0.44)。

要点

  • FPGS辅助下置入基准标记可显著增加机器人SABR系统每分次追踪的标记数量(p<0.001)。
  • 使用FPGS的44个病灶中63.6%追踪2枚、31.8%追踪3枚、4.6%追踪4枚。
  • 两组并发症率均低且无统计学差异(p=0.44),提示该引导系统使用安全。

核心结论

  • 在电磁导航支气管镜置入基准标记时使用FPGS,可能增加机器人SABR系统追踪的基准标记数量,且并发症率低、与未使用FPGS者无统计学差异。

研究设计与样本

  • 单中心回顾性研究,纳入2015年5月至2017年1月接受机器人SABR的肺肿瘤患者共128例、147个治疗病灶;FPGS于2016年5月开始使用,比较使用与未使用FPGS者的中位追踪标记数和并发症率。

主要发现

  • 使用FPGS的44个病灶中,28个(63.6%)追踪2枚标记、14个(31.8%)追踪3枚、2个(4.6%)追踪4枚。
  • 未使用FPGS的103个病灶中,5个(4.9%)追踪1枚、91个(88.4%)追踪2枚、6个(5.8%)追踪3枚、2个(1.9%)追踪4枚。
  • Wilcoxon秩和检验显示使用FPGS的病灶每分次中位追踪标记数显著改善(p<0.001);并发症率低且两组无统计学差异(p=0.44)。

关键数值与推荐

  • 使用FPGS组追踪标记数分布:2枚63.6%、3枚31.8%、4枚4.6%(n=44个病灶)。
  • 未使用FPGS组追踪标记数分布:1枚4.9%、2枚88.4%、3枚5.8%、4枚1.9%(n=103个病灶)。
  • 每分次中位追踪标记数比较p<0.001(Wilcoxon秩和检验);并发症率比较p=0.44。

临床怎么用

  • 对接受机器人SABR的早期NSCLC或复发/寡转移肺病灶患者,在电磁导航支气管镜置入基准标记时可考虑使用FPGS以提高可追踪标记数量。

局限性

  • 为单中心回顾性研究,FPGS于2016年5月起使用,两组间可能存在时间相关混杂,原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic ablative radiotherapy (SABR) is a treatment option for patients with early stage non-small cell lung cancer (NSCLC) and recurrent or oligometastatic disease who are not surgical candidates. Due to the continuous motion of tumors within the lungs, implementing a strategy to track the target lesion is crucial. One method is to place fiducial markers which the robotic SABR system is able to track during treatment. However, placing these markers in a manner that maximizes tracking efficacy can be challenging. Using a novel fiducial placement guidance system (FPGS) during fiducial deployment may offer a way to improve the quantity of fiducials tracked by the robotic SABR system. METHOD: This was an institutional, retrospective review identifying all patients who received robotic SABR for lung tumors from May 2015 until January 2017. The FPGS was instituted in May 2016. The median number of fiducials tracked and the rate of complication was compared between patients whose fiducials were placed using FPGS versus those that were not. RESULTS: A total of 128 patients with 147 treated lung lesions were identified. Of the lesions that utilized FPGS (n = 44), 28 had 2 tracked fiducials (63.6%), 14 had 3 (31.8%) and 2 had 4 (4.6%). Of the lesions treated without FPGS (n = 103), 5 had 1 tracked fiducial (4.9%), 91 had 2 (88.4%), 6 had 3 (5.8%), and 2 had 4 (1.9%). A significant improvement in the median number of fiducials tracked per fraction was observed for the lesions with fiducials placed using FPGS on Wilcoxon rank sum test (p < 0.001). The rate of complication was low and not statistically different between cohorts (p = 0.44). CONCLUSIONS: The FPGS can be used during the deployment of fiducial markers and may increase the number of fiducials tracked. TRIAL REGISTRATION: An exemption for this retrospective review was granted by the East Carolina University IRB under UMCIRB 15-001726.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Stowe H, Ogake S, Sharma S, et al. Improved respiratory motion tracking through a novel fiducial marker placement guidance system during electromagnetic navigational bronchoscopy (ENB). Radiat Oncol. 2019. PMID: 31296231. doi:10.1186/s13014-019-1306-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。